| Identification | Back Directory | [Name]
Cyclopropanecarboxamide, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[5,2-thiazolediyl-(2S)-2,1-pyrrolidinediyl[(1R)-2-oxo-1-phenyl-2,1-ethanediyl]]]bis- | [CAS]
1310694-75-7 | [Synonyms]
MB110
MB-110
MB 110
DBPR110
DBPR-110
DBPR 110
Cyclopropanecarboxamide, N,N'-[[1,1'-biphenyl]-4,4'-diylbis[5,2-thiazolediyl-(2S)-2,1-pyrrolidinediyl[(1R)-2-oxo-1-phenyl-2,1-ethanediyl]]]bis- | [Molecular Formula]
C50H48N6O4S2 | [MDL Number]
MFCD32204472 | [MOL File]
1310694-75-7.mol | [Molecular Weight]
861.09 |
| Hazard Information | Back Directory | [Uses]
DBPR110 is a nonstructural protein 5A (NS5A) inhibitor with inhibitory activity against hepatitis C virus (HCV). DBPR110 exhibited a 50% effective concentration (EC50) of 3.9 ± 0.9 pM and a selectivity index value of over 12,800,000 by reducing HCV1b replicon reporter expression. DBPR110 also effectively reduced the activity of HCV2a replicon with an EC50 of 228.8 pM and a selectivity index value of over 173,130. DBPR110 showed synergy with interferon alpha (IFN-α), NS3 protease inhibitors, and NS5B polymerase inhibitors. The results of DBPR110 suggest that it may be an effective small molecule inhibitor against HCV NS5A[1]. | [References]
[1] Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems |
|
|